BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bhattacharjee A, Reuter S, Trojnár E, Kolodziejczyk R, Seeberger H, Hyvärinen S, Uzonyi B, Szilágyi Á, Prohászka Z, Goldman A, Józsi M, Jokiranta TS. The major autoantibody epitope on factor H in atypical hemolytic uremic syndrome is structurally different from its homologous site in factor H-related protein 1, supporting a novel model for induction of autoimmunity in this disease. J Biol Chem 2015;290:9500-10. [PMID: 25659429 DOI: 10.1074/jbc.M114.630871] [Cited by in Crossref: 47] [Cited by in F6Publishing: 23] [Article Influence: 6.7] [Reference Citation Analysis]
Number Citing Articles
1 Parente R, Clark SJ, Inforzato A, Day AJ. Complement factor H in host defense and immune evasion. Cell Mol Life Sci 2017;74:1605-24. [PMID: 27942748 DOI: 10.1007/s00018-016-2418-4] [Cited by in Crossref: 78] [Cited by in F6Publishing: 80] [Article Influence: 13.0] [Reference Citation Analysis]
2 Yoshida Y, Kato H, Ikeda Y, Nangaku M. Pathogenesis of Atypical Hemolytic Uremic Syndrome. J Atheroscler Thromb 2019;26:99-110. [PMID: 30393246 DOI: 10.5551/jat.RV17026] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
3 Uzonyi B, Szabó Z, Trojnár E, Hyvärinen S, Uray K, Nielsen HH, Erdei A, Jokiranta TS, Prohászka Z, Illes Z, Józsi M. Autoantibodies Against the Complement Regulator Factor H in the Serum of Patients With Neuromyelitis Optica Spectrum Disorder. Front Immunol 2021;12:660382. [PMID: 33986750 DOI: 10.3389/fimmu.2021.660382] [Reference Citation Analysis]
4 Bu F, Borsa NG, Jones MB, Takanami E, Nishimura C, Hauer JJ, Azaiez H, Black-Ziegelbein EA, Meyer NC, Kolbe DL, Li Y, Frees K, Schnieders MJ, Thomas C, Nester C, Smith RJ. High-Throughput Genetic Testing for Thrombotic Microangiopathies and C3 Glomerulopathies. J Am Soc Nephrol 2016;27:1245-53. [PMID: 26283675 DOI: 10.1681/ASN.2015040385] [Cited by in Crossref: 60] [Cited by in F6Publishing: 36] [Article Influence: 8.6] [Reference Citation Analysis]
5 Trojnár E, Józsi M, Uray K, Csuka D, Szilágyi Á, Milosevic D, Stojanović VD, Spasojević B, Rusai K, Müller T, Arbeiter K, Kelen K, Szabó AJ, Reusz GS, Hyvärinen S, Jokiranta TS, Prohászka Z. Analysis of Linear Antibody Epitopes on Factor H and CFHR1 Using Sera of Patients with Autoimmune Atypical Hemolytic Uremic Syndrome. Front Immunol 2017;8:302. [PMID: 28424685 DOI: 10.3389/fimmu.2017.00302] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
6 Thurman JM, Nester CM. All Things Complement. Clin J Am Soc Nephrol 2016;11:1856-66. [PMID: 27340286 DOI: 10.2215/CJN.01710216] [Cited by in Crossref: 43] [Cited by in F6Publishing: 27] [Article Influence: 7.2] [Reference Citation Analysis]
7 Li X, Zong J, Si S. Complement Factor H related protein 1 and immune inflammatory disorders. Molecular Immunology 2022;145:43-9. [DOI: 10.1016/j.molimm.2022.03.117] [Reference Citation Analysis]
8 Kárpáti É, Papp A, Schneider AE, Hajnal D, Cserhalmi M, Csincsi ÁI, Uzonyi B, Józsi M. Interaction of the Factor H Family Proteins FHR-1 and FHR-5 With DNA and Dead Cells: Implications for the Regulation of Complement Activation and Opsonization. Front Immunol 2020;11:1297. [PMID: 32765490 DOI: 10.3389/fimmu.2020.01297] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
9 Brocklebank V, Johnson S, Sheerin TP, Marks SD, Gilbert RD, Tyerman K, Kinoshita M, Awan A, Kaur A, Webb N, Hegde S, Finlay E, Fitzpatrick M, Walsh PR, Wong EKS, Booth C, Kerecuk L, Salama AD, Almond M, Inward C, Goodship TH, Sheerin NS, Marchbank KJ, Kavanagh D. Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland. Kidney Int 2017;92:1261-71. [PMID: 28750931 DOI: 10.1016/j.kint.2017.04.028] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
10 Valoti E, Alberti M, Iatropoulos P, Piras R, Mele C, Breno M, Cremaschi A, Bresin E, Donadelli R, Alizzi S, Amoroso A, Benigni A, Remuzzi G, Noris M. Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS. Front Immunol 2019;10:853. [PMID: 31118930 DOI: 10.3389/fimmu.2019.00853] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
11 Baines AC, Brodsky RA. Complementopathies. Blood Rev 2017;31:213-23. [PMID: 28215731 DOI: 10.1016/j.blre.2017.02.003] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 10.8] [Reference Citation Analysis]
12 Bruel A, Kavanagh D, Noris M, Delmas Y, Wong EKS, Bresin E, Provôt F, Brocklebank V, Mele C, Remuzzi G, Loirat C, Frémeaux-Bacchi V, Fakhouri F. Hemolytic Uremic Syndrome in Pregnancy and Postpartum. Clin J Am Soc Nephrol 2017;12:1237-47. [PMID: 28596415 DOI: 10.2215/CJN.00280117] [Cited by in Crossref: 86] [Cited by in F6Publishing: 37] [Article Influence: 17.2] [Reference Citation Analysis]
13 Palma LMP. Rare and Complex: lessons from a cohort of patients with Atypical Hemolytic Uremic Syndrome. J Bras Nefrol 2021;43:295-6. [PMID: 34057986 DOI: 10.1590/2175-8239-JBN-2021-0066] [Reference Citation Analysis]
14 Sánchez-Corral P, Pouw RB, López-Trascasa M, Józsi M. Self-Damage Caused by Dysregulation of the Complement Alternative Pathway: Relevance of the Factor H Protein Family. Front Immunol 2018;9:1607. [PMID: 30050540 DOI: 10.3389/fimmu.2018.01607] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
15 Noris M, Donadelli R, Remuzzi G. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy. Pediatr Nephrol 2019;34:1311-23. [PMID: 29948306 DOI: 10.1007/s00467-018-3989-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
16 Hannan JP, Laskowski J, Thurman JM, Hageman GS, Holers VM. Mapping the Complement Factor H-Related Protein 1 (CFHR1):C3b/C3d Interactions. PLoS One 2016;11:e0166200. [PMID: 27814381 DOI: 10.1371/journal.pone.0166200] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
17 Durey MA, Sinha A, Togarsimalemath SK, Bagga A. Anti-complement-factor H-associated glomerulopathies. Nat Rev Nephrol 2016;12:563-78. [PMID: 27452363 DOI: 10.1038/nrneph.2016.99] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 9.2] [Reference Citation Analysis]
18 Loeven MA, Maciej-Hulme ML, Yanginlar C, Hubers MC, Kellenbach E, de Graaf M, van Kuppevelt TH, Wetzels J, Rabelink TJ, Smith RJH, van der Vlag J. Selective Binding of Heparin/Heparan Sulfate Oligosaccharides to Factor H and Factor H-Related Proteins: Therapeutic Potential for C3 Glomerulopathies. Front Immunol 2021;12:676662. [PMID: 34489931 DOI: 10.3389/fimmu.2021.676662] [Reference Citation Analysis]
19 Zhang Y, Ghiringhelli Borsa N, Shao D, Dopler A, Jones MB, Meyer NC, Pitcher GR, Taylor AO, Nester CM, Schmidt CQ, Smith RJH. Factor H Autoantibodies and Complement-Mediated Diseases. Front Immunol 2020;11:607211. [PMID: 33384694 DOI: 10.3389/fimmu.2020.607211] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
20 Jokiranta TS. HUS and atypical HUS. Blood. 2017;129:2847-2856. [PMID: 28416508 DOI: 10.1182/blood-2016-11-709865] [Cited by in Crossref: 124] [Cited by in F6Publishing: 101] [Article Influence: 24.8] [Reference Citation Analysis]
21 Palma LMP, Sridharan M, Sethi S. Complement in Secondary Thrombotic Microangiopathy. Kidney Int Rep 2021;6:11-23. [PMID: 33102952 DOI: 10.1016/j.ekir.2020.10.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
22 Puraswani M, Khandelwal P, Saini H, Saini S, Gurjar BS, Sinha A, Shende RP, Maiti TK, Singh AK, Kanga U, Ali U, Agarwal I, Anand K, Prasad N, Rajendran P, Sinha R, Vasudevan A, Saxena A, Agarwal S, Hari P, Sahu A, Rath S, Bagga A. Clinical and Immunological Profile of Anti-factor H Antibody Associated Atypical Hemolytic Uremic Syndrome: A Nationwide Database. Front Immunol 2019;10:1282. [PMID: 31231391 DOI: 10.3389/fimmu.2019.01282] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
23 Yoshida Y, Kato H, Nangaku M. Atypical hemolytic uremic syndrome. Ren Replace Ther 2017;3. [DOI: 10.1186/s41100-016-0088-1] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
24 Tuchscherer A, Chemnitz J. [Hemolytic anemia]. Internist (Berl) 2015;56:1000-8. [PMID: 26245867 DOI: 10.1007/s00108-015-3661-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Gavriilaki E, Brodsky RA. Complementopathies and precision medicine. J Clin Invest 2020;130:2152-63. [PMID: 32310222 DOI: 10.1172/JCI136094] [Cited by in Crossref: 36] [Cited by in F6Publishing: 20] [Article Influence: 36.0] [Reference Citation Analysis]
26 Yokoo T, Tanabe A, Yoshida Y, Caaveiro JMM, Nakakido M, Ikeda Y, Fujimura Y, Matsumoto M, Entzminger K, Maruyama T, Okumura CJ, Nangaku M, Tsumoto K. Antibody recognition of complement Factor H reveals a flexible loop involved in Atypical Hemolytic Uremic Syndrome pathogenesis. J Biol Chem 2022;:101962. [PMID: 35452676 DOI: 10.1016/j.jbc.2022.101962] [Reference Citation Analysis]
27 Jiang H, Fan MN, Yang M, Lu C, Zhang M, Liu XH, Ma L. Association among Complement Factor H Autoantibodies, Deletions of CFHR, and the Risk of Atypical Hemolytic Uremic Syndrome. Int J Environ Res Public Health 2016;13:E1209. [PMID: 27929404 DOI: 10.3390/ijerph13121209] [Cited by in Crossref: 6] [Article Influence: 1.0] [Reference Citation Analysis]
28 Li LL, Tan Y, Song D, Li YZ, Yu F, Chen M, Zhao MH. Anti-complement factor H autoantibodies may be protective in lupus nephritis. Clin Chim Acta 2020;508:1-8. [PMID: 32387092 DOI: 10.1016/j.cca.2020.05.005] [Reference Citation Analysis]
29 Münch J, Bachmann A, Grohmann M, Mayer C, Kirschfink M, Lindner TH, Bergmann C, Halbritter J. Effective immunosuppressive management with belatacept and eculizumab in post-transplant aHUS due to a homozygous deletion of CFHR1/CFHR3 and the presence of CFH antibodies. Clin Kidney J 2017;10:742-6. [PMID: 29225802 DOI: 10.1093/ckj/sfx053] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]